almotriptan has been researched along with ergotamine in 5 studies
| Studies (almotriptan) | Trials (almotriptan) | Recent Studies (post-2010) (almotriptan) | Studies (ergotamine) | Trials (ergotamine) | Recent Studies (post-2010) (ergotamine) |
|---|---|---|---|---|---|
| 188 | 59 | 42 | 2,352 | 103 | 103 |
| Protein | Taxonomy | almotriptan (IC50) | ergotamine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.056 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 6.499 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.16 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.761 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 4.142 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0021 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0043 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0038 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.012 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0008 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.728 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.064 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.049 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0065 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.056 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0008 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0043 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0035 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Csiba, L; Ficzere, A | 1 |
| Galván, J; Heras, J; Láinez, MJ; Vila, C | 1 |
| Comas, A; Heras, J; Láinez, JM; Slof, J | 1 |
| Autret-Leca, E; Beau-Salinas, F; Bensouda-Grimaldi, L; Cissoko, H; Jonville-Béra, AP | 1 |
1 review(s) available for almotriptan and ergotamine
| Article | Year |
|---|---|
[Treatment of migraine in patients with hypertension and ischemic heart disease].
Topics: Adjuvants, Pharmaceutic; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Contraindications; Dihydroergotamine; Dopamine Agonists; Ergotamine; Humans; Hypertension; Indoles; Migraine Disorders; Myocardial Ischemia; Oxazolidinones; Retrospective Studies; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines; Vasoconstrictor Agents | 2002 |
1 trial(s) available for almotriptan and ergotamine
| Article | Year |
|---|---|
Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.
Topics: Acute Disease; Adult; Caffeine; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Ergotamine; Female; Humans; Male; Migraine Disorders; Nausea; Patient Satisfaction; Phosphodiesterase Inhibitors; Photophobia; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines; Vasoconstrictor Agents | 2007 |
3 other study(ies) available for almotriptan and ergotamine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
[Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis].
Topics: Analgesics, Non-Narcotic; Caffeine; Cost-Benefit Analysis; Costs and Cost Analysis; Ergotamine; Health Care Costs; Humans; Migraine Disorders; Patient Satisfaction; Quality of Life; Treatment Outcome; Tryptamines | 2009 |
Drug dependence associated with triptans and ergot derivatives: a case/non-case study.
Topics: Claviceps; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Risk; Substance-Related Disorders; Sumatriptan; Tryptamines | 2010 |